- Trials with a EudraCT protocol (369)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
369 result(s) found for: Serology.
Displaying page 1 of 19.
EudraCT Number: 2007-003692-39 | Sponsor Protocol Number: PCV-ESA 2006 | Start Date*: 2006-03-08 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA | |||||||||||||
Full Title: Evaluation of immunogenicity of 7-valent Pneumococcal Conjugate Vaccine (Prevenar) and Hexavalent DtPa-HBV-IPV-Hib (InfaNrix Hexa), co-administered at the same time, versus Hexavalent vaccine, use... | |||||||||||||
Medical condition: Healthy children | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001836-12 | Sponsor Protocol Number: ITMC0414 | Start Date*: 2014-07-31 |
Sponsor Name:Institute of Tropical Medicine | ||
Full Title: Boostability for rabies in last-minute travelers: One Day Rabies Pre-exposure Intradermal Vaccination followed by one day Postexposure Intradermal Vaccination | ||
Medical condition: Rabies is a viral infection that affects the central nervous system. It causes encephalitis which is almost invariably fatal. Preventive vaccination alone implies no complete protection, but simpli... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005598-28 | Sponsor Protocol Number: ADG20PREV001 | Start Date*: 2021-09-17 | |||||||||||
Sponsor Name:Adagio Therapeutics Inc | |||||||||||||
Full Title: A Phase 2/3 Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE) | |||||||||||||
Medical condition: The prevention of symptomatic coronavirus (CoV) disease 2019 (COVID 19) in adults and adolescents | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) PL (Prematurely Ended) CZ (Completed) BG (Completed) RO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000413-17 | Sponsor Protocol Number: COVERS | Start Date*: 2021-02-24 |
Sponsor Name:Region Skåne - Kliniska Studier Sverige, Forum Söder | ||
Full Title: COVERS (COVID-Vaccination Efficiency Risk and Safety Study) - an open trial for follow-up of efficacy, risk and safety in persons who have been vaccinated against SARS-CoV-2 in Region Skåne with va... | ||
Medical condition: Coronavirus disease 2019 (COVID-19) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004905-15 | Sponsor Protocol Number: DNDi-FEX-12-CH | Start Date*: 2017-09-13 |
Sponsor Name:Drugs for Neglected Diseases initiative (DNDi) | ||
Full Title: Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study to Evaluate Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients with Chronic Indeterminate Chagas Disease | ||
Medical condition: Chagas disease (CD) is a disease caused by Trypanosoma cruzi, ranking among the world’s most neglected diseases. There is significant associated morbidity and mortality, particularly in chronic ph... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006773-32 | Sponsor Protocol Number: HPV_CSP01 | Start Date*: 2009-05-20 | |||||||||||
Sponsor Name:Health Protection Agency | |||||||||||||
Full Title: A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines | |||||||||||||
Medical condition: This study will investigate vaccines that prevent premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. This study will investigate wheth... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005582-13 | Sponsor Protocol Number: CHUBX2020/26 | Start Date*: 2021-03-03 |
Sponsor Name:CHU de Bordeaux | ||
Full Title: Prospective pilot study evaluating a therapeutic synergy between the infusion of CMV-specific immunoglobulins and the level before transplantation of negative gamma delta Vdelta 2 T lymphocytes exp... | ||
Medical condition: CMV infection in transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000781-15 | Sponsor Protocol Number: COVFATI | Start Date*: 2021-12-14 |
Sponsor Name:Amsterdam UMC VUmc | ||
Full Title: Neuroinflammation and post-infectious fatigue in individuals with and without Covid-19 | ||
Medical condition: Chronic fatigue after COVID-19 infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019057-17 | Sponsor Protocol Number: SPC3649-203 | Start Date*: 2010-07-13 |
Sponsor Name:Santaris Pharma A/S | ||
Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (miravirsen) Administered ... | ||
Medical condition: Patients infected with chronic hepatitis C | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) DE (Completed) SK (Completed) PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001536-98 | Sponsor Protocol Number: PREPSARS | Start Date*: 2020-04-18 |
Sponsor Name:HOSPITAL UNIVERSITARI MÚTUA TERRASSA | ||
Full Title: Prophylaxis of COVID-19 infection with hydroxychloroquine in healthcare personnel with high risk of infection. | ||
Medical condition: COVID-19 infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002503-19 | Sponsor Protocol Number: 62586 | Start Date*: 2020-07-08 | |||||||||||
Sponsor Name:UMC Utrecht | |||||||||||||
Full Title: BCG vaccination to Reduce the impact of COVID-19 in healthcare workers (BRACE) Trial | |||||||||||||
Medical condition: SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000287-32 | Sponsor Protocol Number: D325AC00002 | Start Date*: 2020-12-02 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD) | |||||||||||||
Medical condition: Bullous Pemphigoid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended) FR (Completed) IT (Prematurely Ended) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014719-11 | Sponsor Protocol Number: 2009/08 H1N1 | Start Date*: 2009-09-18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University of Oxford | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Baxter H1N1 vaccine and GlaxoSmithKline H1N1 vaccine in children 6 months to 12... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Prophylaxis of influenza in an officially declared pandemic situation. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-005047-32 | Sponsor Protocol Number: H-100-002 | Start Date*: 2018-09-27 | |||||||||||
Sponsor Name:Hookipa Biotech GmbH | |||||||||||||
Full Title: A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Sero... | |||||||||||||
Medical condition: Prevention of clinically significant cytomegalovirus (CMV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) BE (Completed) FR (Completed) AT (Completed) NO (Completed) DE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002894-36 | Sponsor Protocol Number: IXIARO-booster-senescence | Start Date*: 2017-12-22 |
Sponsor Name:Medical University of Vienna (MUW) | ||
Full Title: "An open, monocentric, uncontrolled phase 4 trial to characterise cellular and humoral immune responses following the first booster immunisation with the inactivated, purified Japanese Encephalitis... | ||
Medical condition: The condition under investigation is the naturally aging immune system. The aim of this study is to investigate the immune responses following a booster immunisation with the Japanese Encephalitis ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002767-95 | Sponsor Protocol Number: 12/0161 | Start Date*: 2013-06-17 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Long term antibody response to CMV gB vaccine in patients requiring liver or renal transplant. A Phase II open, single-site study, in participants who received CMV gB vaccine or placebo in previous... | |||||||||||||
Medical condition: Cytomegalovirus. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001565-37 | Sponsor Protocol Number: PrEP_COVID | Start Date*: 2020-04-03 |
Sponsor Name:ISGlobal | ||
Full Title: PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE FOR HIGH-RISK HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC (PrEP_COVID): A UNICENTRIC, DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL. | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001717-11 | Sponsor Protocol Number: CYD32 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2008-000086-38 | Sponsor Protocol Number: FARM6KMZFY | Start Date*: 2008-04-10 | |||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | |||||||||||||
Full Title: A PHASE 2, SINGLE ARM, MULTI-CENTER STUDY ON THE BENEFIT/COST/SAFETY PROFILE OF LOW-DOSE RITUXIMAB FOR REFRACTORY MIXED CRYOGLOBULINEMIA | |||||||||||||
Medical condition: Mixed cryoglobulinemia (type II or III) associated with chronic HCV infection (positive serology and/or HCV viremia) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002808-25 | Sponsor Protocol Number: AI444-281 | Start Date*: 2015-04-16 |
Sponsor Name:Academic Medical Center Amsterdam | ||
Full Title: Immune phenotyping in chronic hepatitis C patients treated with Sofosbuvir and Daclatasvir combination with or without Ribavirin for 12 or 24 weeks -SODA study | ||
Medical condition: Chronic hepatitis C | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
